Germany · Delayed Price · Currency is EUR Entera Bio Statistics
Total Valuation
Entera Bio has a market cap or net worth of EUR 94.12 million. The enterprise value is 86.91 million.
| Market Cap | 94.12M |
| Enterprise Value | 86.91M |
Important Dates
The next estimated earnings date is Monday, March 9, 2026.
| Earnings Date | Mar 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 45.86M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +25.17% |
| Shares Change (QoQ) | +0.54% |
| Owned by Insiders (%) | 1.96% |
| Owned by Institutions (%) | 12.06% |
| Float | 31.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 890.60 |
| PB Ratio | 7.25 |
| P/TBV Ratio | 7.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.46 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -14.39 |
Financial Position
The company has a current ratio of 10.83, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.83 |
| Quick Ratio | 5.46 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.03 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -99.43% and return on invested capital (ROIC) is -60.93%.
| Return on Equity (ROE) | -99.43% |
| Return on Assets (ROA) | -53.80% |
| Return on Invested Capital (ROIC) | -60.93% |
| Return on Capital Employed (ROCE) | -68.35% |
| Revenue Per Employee | 5,033 |
| Profits Per Employee | -437,555 |
| Employee Count | 20 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Entera Bio has paid 11,932 in taxes.
| Income Tax | 11,932 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +34.23% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +34.23% |
| 50-Day Moving Average | 2.04 |
| 200-Day Moving Average | 1.77 |
| Relative Strength Index (RSI) | 41.45 |
| Average Volume (20 Days) | 52 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.01 |
Income Statement
In the last 12 months, Entera Bio had revenue of EUR 105,685 and -9.19 million in losses. Loss per share was -0.21.
| Revenue | 105,685 |
| Gross Profit | n/a |
| Operating Income | -9.23M |
| Pretax Income | -9.18M |
| Net Income | -9.19M |
| EBITDA | -9.20M |
| EBIT | -9.23M |
| Loss Per Share | -0.21 |
Balance Sheet
The company has 7.31 million in cash and 179,835 in debt, giving a net cash position of 7.13 million.
| Cash & Cash Equivalents | 7.31M |
| Total Debt | 179,835 |
| Net Cash | 7.13M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 12.98M |
| Book Value Per Share | 0.28 |
| Working Capital | 13.16M |
Cash Flow
In the last 12 months, operating cash flow was -5.97 million and capital expenditures -70,741, giving a free cash flow of -6.04 million.
| Operating Cash Flow | -5.97M |
| Capital Expenditures | -70,741 |
| Free Cash Flow | -6.04M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -8,729.05% |
| Pretax Margin | -8,683.08% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Entera Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.17% |
| Shareholder Yield | -25.17% |
| Earnings Yield | -9.76% |
| FCF Yield | -6.42% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Entera Bio has an Altman Z-Score of 11.83 and a Piotroski F-Score of 2.
| Altman Z-Score | 11.83 |
| Piotroski F-Score | 2 |